Electrolytes, NMJ Action Potential & Anesthesia Medications

Study safety note: This is for exam review and pattern recognition. Actual anesthesia decisions depend on acuity, ECG, renal function, disease state, degree/timing of abnormality, and institutional practice. Use quantitative twitch monitoring whenever paralytics are involved.

Start Here: The NMJ “3-Step Flow”

1. Nerve AP arrives→ 2. Ca²⁺ enters presynaptic terminal→ 3. ACh released→ Nicotinic receptor opens→ Na⁺ in / K⁺ out→ Muscle contraction

Anchor: anything that decreases presynaptic Ca²⁺ entry or decreases excitability tends to decrease ACh release and/or muscle response. Anything that increases ACh at the cleft tends to oppose nondepolarizers and prolong depolarizing block.

Board-style shortcut:
↑ ACh at NMJ → resistance to NDMRs + prolonged succinylcholine
↓ ACh at NMJ → potentiated NDMRs + possible weakness

Patient Electrolyte Flow-Sheet

Pick the abnormality and follow the medication implications.

High-Yield Electrolyte Cards

Potassium K⁺

Resting membrane potential Sux warning

K⁺ sets the resting membrane potential. Too high or too low can cause weakness, arrhythmias, and abnormal response to paralysis.

↑K⁺ Hyperkalemia

Membrane: depolarized resting potential; severe cases inactivate Na⁺ channels → weakness/paralysis.
ACh release: not the main issue; the main issue is membrane excitability and cardiac risk.
Succinylcholine: avoid/think hard if significant hyperkalemia or receptor upregulation risk. Sux normally raises K⁺ about 0.5 mEq/L, but can cause massive K⁺ release with burns, denervation, spinal cord injury, stroke with residual symptoms, etc.
NDMRs: usually preferred over sux when K⁺ risk is high.

↓K⁺ Hypokalemia

Membrane: hyperpolarized → harder to fire AP → weakness.
ACh release: not primarily changed; muscle response is reduced.
NDMRs: potentiated/prolonged. Use smaller doses, monitor TOF.
Reversal: weakness can persist even if reversal is adequate.

Calcium Ca²⁺

ACh release trigger Opposes Mg

Ca²⁺ entry into the presynaptic terminal triggers ACh vesicle release.

↑Ca²⁺ Hypercalcemia

ACh release: tends to support/increase release.
Membrane: less excitable clinically; weakness and arrhythmias may occur.
NDMRs: may antagonize blockade somewhat; also calcium can partially reverse Mg-related weakness.
Watch: shortened QT, dysrhythmias, volume depletion.

↓Ca²⁺ Hypocalcemia

ACh release: less presynaptic trigger → decreased ACh release tendency.
Membrane: more irritable/tetany, but NMJ transmission can be weaker.
NDMRs: potentiated/prolonged.
MgSO₄ connection: magnesium toxicity and hypocalcemia both push toward weakness/NMB potentiation.

Magnesium Mg²⁺

Blocks Ca entry Potentiates NDMR

Mg²⁺ is the “turn down ACh release” electrolyte. It antagonizes presynaptic Ca²⁺ entry.

↑Mg²⁺ Hypermagnesemia / MgSO₄

ACh release: decreased because Mg blocks Ca-mediated vesicle release.
NDMRs: potentiated/prolonged. Lower dose + TOF.
Succinylcholine: may prolong weakness/respiratory depression clinically, though classic board pairing is Mg + prolonged nondepolarizers.
Reversal: neostigmine may be less satisfying if the issue is presynaptic ACh release. Calcium can help Mg toxicity.

↓Mg²⁺ Hypomagnesemia

ACh release/excitability: increased neuromuscular irritability, tremor, arrhythmias.
NDMRs: possible relative resistance/less potentiation compared with normal, but clinical data are less clean.
Watch: torsades risk, especially with low K⁺/low Ca²⁺.

Sodium Na⁺

AP upstroke Mostly indirect

Na⁺ carries the rapid depolarizing upstroke of the action potential. Sodium disorders are usually more CNS/osmolality/cardiovascular issues than direct NMJ drug-interaction issues.

↑Na⁺ Hypernatremia

AP/NMJ: not a classic direct ACh-release interaction.
Anesthesia concern: dehydration, altered mentation, intracranial risk if corrected too fast.
NMB: use monitoring; do not predict dose changes based on Na⁺ alone.

↓Na⁺ Hyponatremia

AP/NMJ: severe low Na⁺ decreases gradient for depolarization and causes CNS symptoms.
Anesthesia concern: seizures, cerebral edema, aspiration risk, careful correction.
NMB: not a classic direct ACh interaction; weakness may be multifactorial.

Phosphate Phos

ATP Respiratory weakness

Phosphate is not a direct ACh-release electrolyte, but it is huge for ATP and muscle strength.

↓Phosphate Hypophosphatemia

ACh release: not the direct mechanism.
Muscle: ATP depletion → skeletal/respiratory muscle weakness.
Anesthesia meds: may look like prolonged paralysis or poor respiratory mechanics after reversal.
Think: refeeding, DKA treatment, alcoholism, malnutrition.

Chloride Cl⁻

Membrane stability Indirect NMJ role

Chloride helps stabilize the resting membrane and is tightly linked with acid-base balance.

↑Cl⁻ Hyperchloremia

Membrane: can contribute to metabolic acidosis.
NMJ: indirect → acidosis can potentiate NDMRs.
Clinical: decreased contractility, hemodynamic changes.

↓Cl⁻ Hypochloremia

Membrane: often associated with metabolic alkalosis.
NMJ: alkalosis → ↓ ionized Ca²⁺ → neuromuscular irritability.
Clinical: tetany, weakness, altered NMB response.

Acid–Base Modifier

Changes NMB response

Not an electrolyte by itself, but acid-base status changes protein binding, ionization, K⁺ shifts, and NMB behavior.

Acidosis / hypercarbia

K⁺: can worsen hyperkalemia.
NDMRs: often potentiated/prolonged.
Local anesthetics: acidosis worsens LAST risk and reduces efficacy of local anesthetics in infected/acidic tissue.

Alkalosis

K⁺/Ca²⁺: shifts K⁺ intracellularly; increases protein binding of Ca²⁺ → can create symptoms of low ionized Ca²⁺.
Clinical: paresthesias, tetany, irritability.

Medication Impact Cheat Sheet

Medication / class	When electrolytes matter	High-yield exam takeaway
Succinylcholine	Hyperkalemia or receptor upregulation states. Normal muscle releases some K⁺; upregulated extrajunctional receptors can release dangerous K⁺.	Avoid in high K⁺ risk states. Anticholinesterases can prolong depolarizing blockade.
Rocuronium / vecuronium / cisatracurium NDMRs	Potentiated by hypokalemia, hypocalcemia, hypermagnesemia, acidosis, hypothermia, aminoglycosides, lithium, volatile agents.	Electrolyte weakness + NDMR = prolonged weakness. Use TOF, reduce/re-dose carefully.
Neostigmine / edrophonium AChE inhibitors used for reversal	Increase ACh to compete against NDMR. Less useful if weakness is from Mg toxicity, profound electrolyte abnormality, or deep block.	Reversal increases ACh: helps NDMR, but can prolong succinylcholine if present before/with sux.
Tacrine / donepezil / rivastigmine central AChE inhibitors	Increase ACh. Can prolong succinylcholine and cause resistance to NDMRs.	↑ACh = sux prolonged + NDMR resistance.
Magnesium sulfate	Decreases Ca-mediated ACh release; common in OB/preeclampsia.	Potentiates NDMRs. Calcium can treat magnesium toxicity.
Aminoglycosides gentamicin, tobramycin, etc.	Can impair presynaptic ACh release and postsynaptic sensitivity; worse with Mg, hypocalcemia, renal issues.	Can potentiate NMB; calcium may partially reverse aminoglycoside-associated weakness.
Volatile anesthetics	Potentiate NDMRs; electrolyte abnormalities can compound weakness.	Less NDMR may be needed under volatile anesthetic.
Local anesthetics	Block voltage-gated Na⁺ channels. Acidosis and hyperkalemia/cardiac disease increase toxicity concern.	LA mechanism is Na⁺ channel block, not ACh release. Watch LAST risk with acidosis.

Fast “If Labs Say This, Think This” Flow

Lab pattern	NMJ idea	Anesthesia move
↑K⁺	Depolarized membrane, arrhythmia risk	Avoid sux if clinically significant or high-risk condition; use NDMR + TOF
↓K⁺	Hyperpolarized, weak muscle response	NDMR potentiation/prolongation; correct K⁺ when appropriate
↑Mg²⁺	↓Ca entry → ↓ACh release	NDMR potentiation; reduce dose; consider calcium if toxicity
↓Ca²⁺	↓ACh release trigger + weakness	NDMR potentiation; correct ionized Ca²⁺ if symptomatic/clinically indicated
↑AChE inhibitor on med list	↑ACh at NMJ	Sux prolonged; NDMR resistance; plan monitoring
↓Phos	Low ATP → respiratory weakness	May fail extubation despite “reversed” TOF; correct cause

Mini Check-Yourself Quiz

1. Patient on MgSO₄ receives rocuronium. What do you expect?

Correct: Magnesium blocks presynaptic Ca²⁺ entry, decreasing ACh release and potentiating nondepolarizers.

2. Which med pattern is most likely to prolong succinylcholine?

Correct: AChE inhibitors increase ACh and can prolong depolarizing blockade while causing relative resistance to NDMRs.

3. Hypokalemia generally does what to NDMRs?

Correct: Hypokalemia is associated with enhanced/prolonged nondepolarizing blockade and muscle weakness.

Memory Hooks

Mg = “Mutes” ACh. Mg blocks Ca entry → less ACh release → NDMRs hit harder.

Ca = “Causes” vesicle release. Ca entry triggers ACh vesicles.

K = “Keeps” resting potential. Too high or too low = weak/unstable membrane.

↑ACh rule: “ACh helps muscle beat NDMR, but makes Sux stay longer.”